MEI Pharma Statistics
Share Statistics
MEI Pharma has 6.66M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 6.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.58M |
| Failed to Deliver (FTD) Shares | 335 |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 80.97K, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 80.97K |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 0.94 |
Valuation Ratios
The PE ratio is 1.07 and the forward PE ratio is -0.85.
| PE Ratio | 1.07 |
| Forward PE | -0.85 |
| PS Ratio | 0.29 |
| Forward PS | 0.7 |
| PB Ratio | 0.58 |
| P/FCF Ratio | -0.38 |
| PEG Ratio | n/a |
Enterprise Valuation
MEI Pharma Inc. has an Enterprise Value (EV) of 39.66M.
| EV / Earnings | 2.23 |
| EV / Sales | 0.61 |
| EV / EBITDA | 1.5 |
| EV / EBIT | 2.73 |
| EV / FCF | -0.79 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.
| Current Ratio | 4.88 |
| Quick Ratio | 4.88 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.54% and return on capital (ROIC) is 44.04%.
| Return on Equity (ROE) | 0.54% |
| Return on Assets (ROA) | 0.43% |
| Return on Capital (ROIC) | 44.04% |
| Revenue Per Employee | 2.33M |
| Profits Per Employee | 634.93K |
| Employee Count | 28 |
| Asset Turnover | 1.58 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -46.59% in the last 52 weeks. The beta is 0.71, so MEI Pharma 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -46.59% |
| 50-Day Moving Average | 2.76 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 58.85 |
| Average Volume (20 Days) | 52.37K |
Income Statement
In the last 12 months, MEI Pharma had revenue of 65.30M and earned 17.78M in profits. Earnings per share was 2.67.
| Revenue | 65.30M |
| Gross Profit | 64.91M |
| Operating Income | 14.54M |
| Net Income | 17.78M |
| EBITDA | 26.38M |
| EBIT | 14.54M |
| Earnings Per Share (EPS) | 2.67 |
Balance Sheet
The company has 3.71M in cash and 0 in debt, giving a net cash position of 3.71M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | 0 |
| Net Cash | 3.71M |
| Retained Earnings | -388.22M |
| Total Assets | 27.75M |
| Working Capital | 24.87M |
Cash Flow
In the last 12 months, operating cash flow was -50.47M and capital expenditures -7.00K, giving a free cash flow of -50.48M.
| Operating Cash Flow | -50.47M |
| Capital Expenditures | -7.00K |
| Free Cash Flow | -50.48M |
| FCF Per Share | -7.58 |
Margins
Gross margin is 99.41%, with operating and profit margins of 22.27% and 27.23%.
| Gross Margin | 99.41% |
| Operating Margin | 22.27% |
| Pretax Margin | 27.23% |
| Profit Margin | 27.23% |
| EBITDA Margin | 40.4% |
| EBIT Margin | 22.27% |
| FCF Margin | -77.31% |
Dividends & Yields
MEIP pays an annual dividend of $1.75, which amounts to a dividend yield of 64.34%.
| Dividend Per Share | $1.75 |
| Dividend Yield | 64.34% |
| Dividend Growth (YoY) | 0% |
| Payout Ratio | -25.04% |
| Earnings Yield | 97.45% |
| FCF Yield | -276.51% |
Analyst Forecast
The average price target for MEIP is $7, which is 155.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 155.5% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Apr 17, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 17, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -19.85 |
| Piotroski F-Score | 1 |